Form 4: Kezar Life Sciences Executive Acquires Stock Options Following Performance Milestone

Mark C. Schiller, Chief Legal Officer of Kezar Life Sciences, gains rights to purchase 7,200 shares of common stock following achievement of performance criteria.

Summary

• Mark C. Schiller, Chief Legal Officer of Kezar Life Sciences, was granted an option to purchase 12,000 shares of common stock on July 11, 2024.
• The option vests on July 11, 2025, contingent upon achieving non-financial performance criteria and continued service.
• On March 4, 2025, the company's Compensation Committee certified that performance criteria were met for 7,200 shares.
• As a result, Schiller will have the right to purchase 7,200 shares on July 11, 2025, if he continues to provide service.
• The exercise price of the options is $6.30 per share, and the options expire on July 10, 2034.
• Following this transaction, Schiller beneficially owns 7,200 derivative securities.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The vesting of options indicates achievement of performance goals, which is a positive sign. However, it's a routine event and doesn't necessarily indicate a major shift in the company's prospects.

Positives

• Achievement of performance criteria triggers vesting of stock options for a key executive, potentially aligning interests with shareholders.
• The vesting of options is tied to continued service, incentivizing the executive to remain with the company.

Future Outlook

The executive will be able to exercise the options on July 11, 2025, if they continue to provide service to the company.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, used to incentivize performance and align executive interests with those of shareholders.

Comparison to Industry Standards

• Stock option grants are a typical component of compensation packages for executives in biotech companies like Kezar Life Sciences.
• Companies such as Amgen, Gilead Sciences, and Biogen also utilize stock options as part of their executive compensation plans.
• The vesting schedules and performance criteria associated with these options vary across companies, but the general purpose is to incentivize long-term value creation.

Stakeholder Impact

• Shareholders may view the vesting of options as a positive sign, indicating that the executive is incentivized to create long-term value.
• Employees may see this as a positive sign of the company's commitment to rewarding performance.

Next Steps

• The executive will need to continue providing service to the company through July 11, 2025, to fully vest the options.
• The executive may choose to exercise the options after the vesting date, subject to applicable regulations and company policies.

Key Dates